Global Ornithine-Transcarbamylase Deficiency Market Size By Product Type (DTX-301, SEL-313, SHP-641, PRX-OTC), By End-User (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geographic Scope And Forecast

Ornithine-Transcarbamylase Deficiency Market Size And Forecast

Ornithine-Transcarbamylase Deficiency Market size was valued at USD 688.74 Million in 2024 and is projected to reach USD 930.33 Million by 2031, growing at a CAGR of 3.83% from 2024 to 2031.

An increase in the number of awareness campaigns run by key players of the Ornithine-Transcarbamylase Deficiency Market for families and healthcare experts has boosted the market development for ornithine transcarbamylase insufficiency treatment. The Global Ornithine-Transcarbamylase Deficiency Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

To Get Detailed Analysis: Download Report PDF

Global Ornithine-Transcarbamylase Deficiency Market Definition

Ammonia builds up in the bloodstream due to Ornithine Transcarbamylase deficiency, a hereditary condition. When proteins are broken down inside the body, ammonia is produced, which can be harmful if quantities rise too high. Excess ammonia has a particularly negative impact on the nervous system. Deficiency in ornithine transcarbamylase can occur at any age. In the first few days of life, the most severe form occurs. Males are more likely than females to develop this neonatal-onset variant of the illness. A newborn with neonatal-onset ornithine transcarbamylase deficiency may be getting lethargic or hesitant to eat, and his or her respiration rate and body temperature may be uncontrollably high. Because ammonia is particularly harmful to the nervous system, ornithine transcarbamylase deficiency results in neurological issues as well as liver disease.

The incidence of ornithine transcarbamylase deficiency has been estimated to be between 1 in 14,000 and 1 in 77,000 people. Because patients with the late-onset form of the illness are less likely to seek medical help, those with the neonatal-onset variant are more likely to be included in these estimations. OTC deficiency is a hereditary disease that is passed down through the X-chromosome. Males are more likely than females to be affected by OTC deficiency, which is only completely manifested in males. Symptoms in males usually appear in the first few days of infancy, however, late-onset OTC deficiency might appear later in life.

Approximately 20% of carrier females experience modest symptoms of the illness, and only a small percentage of them are severely affected as children. Pediatricians, geneticists, dieticians, neurologists, neurologists, and physicians make up a multidisciplinary team. The goal of treatment for OTC deficiency is to prevent excessive ammonia formation or to remove excessive ammonia. Dietary limitations in people with OTC deficiency are designed to keep protein consumption to a minimum to avoid ammonia buildup. Infants with OTC deficiency are put on a high-calorie, low-protein diet that includes necessary amino acids. Medications that promote the elimination of nitrogen from the body are also used to treat people with OTC deficiency.

What's inside a VMR
industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

>>> Ask For Discount @ – https://www.verifiedmarketresearch.com/ask-for-discount/?rid=26870

Global Ornithine-Transcarbamylase Deficiency Market Overview

COVID-19 patients with ornithine transcarbamylase deficiency are at a higher risk. In such patients, this illness has resulted in previous comorbidities. The industry is being driven by an alarming surge in COVID-19 instances among patients who also have ornithine transcarbamylase deficiency. Patients with other co-morbidities, such as diabetes, hypertension, or kidney disease, are especially vulnerable to COVID-19. Evidence has shown that patients who are weak in OTCs are more vulnerable. As a result, healthcare providers are constantly seeking to boost the availability of essential pharmaceuticals.

Ornithine transcarbamylase deficiency has been linked to a large number of cases of sudden infant death syndrome (SIDS). COVID-19 vaccines are providing revenue prospects for companies in the Ornithine-Transcarbamylase Deficiency Market. This is expected to keep demand afloat for the duration of the epidemic, maximizing company margins and maintaining consistent cash flow. The Ornithine-Transcarbamylase Deficiency Market is benefiting from this reason. Furthermore, an increase in the number of awareness programs for families and healthcare professionals performed by key companies in the Ornithine-Transcarbamylase Deficiency Market has supported the market growth for ornithine transcarbamylase deficiency treatment.

The Global Ornithine-Transcarbamylase Deficiency Market is expected to be fueled by an increase in the number of patients with ornithine transcarbamylase (OTC) deficiency. Major factors that are driving the global Ornithine-Transcarbamylase Deficiency Market include the implementation of novel therapies for ornithine transcarbamylase (OTC) deficiency treatment, favorable reimbursement policies for OTC deficiency treatment, and various patient assistance programs provided by several international and regional organizations. One of the reasons that could slow the market’s growth is a lack of data on the prognosis & diagnosis of the OTC deficiency treatment. The supply chain for the raw material needed to make medications for OTC deficiency has been interrupted in numerous countries as a result of COVID-19.

Furthermore, due to the pandemic, medicine makers have halted their manufacturing, resulting in a decline in pharmaceutical industry growth. This is predicted to have a big influence on the market for ornithine transcarbamylase deficient treatments. To extend their product range, key companies in the global Ornithine-Transcarbamylase Deficiency Market are acquiring emerging players. Companies prefer to buy rising players’ R&D units to collaborate on revolutionary technology. The strategy provides businesses with an enormous opportunity to leverage manufacturing and commercialize products.

Market Attractiveness

The image of market attractiveness provided would further help to get information about the region that is majorly leading in the Global Ornithine-Transcarbamylase Deficiency Market. We cover the major impacting factors that are responsible for driving the industry growth in the given region.

Porter’s Five Forces

The image provided would further help to get information about Porter’s five forces framework providing a blueprint for understanding the behavior of competitors and a player’s strategic positioning in the respective industry. Porter’s five forces model can be used to assess the competitive landscape in the Global Ornithine-Transcarbamylase Deficiency Market, gauge the attractiveness of a certain sector, and assess investment possibilities.

Global Ornithine-Transcarbamylase Deficiency Market Segmentation Analysis

The Global Ornithine-Transcarbamylase Deficiency Market is Segmented on the basis of Product Type, End-User, And Geography.

Ornithine-Transcarbamylase Deficiency Market, By Product Type

• DTX-301
• SEL-313
• SHP-641
• PRX-OTC
• Others

Based on Product Type, the market is bifurcated into DTX-301, SEL-313, SHP-641, PRX-OTC, and Others. The DTX 301 segment holds the largest market share during the forecast period. DTX 301 is an investigational AAV gene therapy being developed for the treatment of individuals with ornithine transcarbamylase (OTC) deficiency.

Ornithine-Transcarbamylase Deficiency Market, By End-User

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Based on End-User, the market is bifurcated into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Because of the larger number of prescriptions filled at these hospital pharmacies, strong supply chain management, favorable reimbursement scenarios, and various patient assistance programs run by pharmaceutical companies, the hospital pharmacies segment accounted for a significant portion of the market.

Ornithine-Transcarbamylase Deficiency Market, By Geography

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

On the basis of Regional Analysis, the Global Ornithine-Transcarbamylase Deficiency Market is classified into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America holds the largest market share. The availability of well-defined reimbursement policies from public and private health insurance firms, which help provide patients easy access to diagnosis, and ongoing projects will boost the market in the North American region.

Key Players

The “Global Ornithine-Transcarbamylase Deficiency Market” study report will provide valuable insight with an emphasis on the global market including some of the major players such as Abbott, Nutricia, Ultragenyx Pharmaceuticals, Acer Therapeutics, Bausch Health Companies Inc, Mead Johnson, Arcturus Therapeutics Inc, Horizon Therapeutics, Nestle, OrphanPacific Inc.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

• Feb 8, 2023 – Abbott and Cardiovascular Systems, Inc. (CSI) announced a definitive agreement for Abbott to acquire CSI, a medical device company with an innovative atherectomy system used in treating peripheral and coronary artery disease. Under terms of the agreement, CSI stockholders will receive $20 per common share at a total expected equity value of approximately $890 million.
• Dec 19, 2022 – Abbot announced the U.S. Food and Drug Administration (FDA) approval of the company’s Eterna™ spinal cord stimulation (SCS) system – the smallest implantable, rechargeable spinal cord stimulator currently available on the market for the treatment of chronic pain.*4 Eterna SCS utilizes Abbott’s proprietary low-dose BurstDR™ stimulation, the only SCS waveform technology with the highest level of clinical evidence (1A evidence), proven to reduce pain 23% more than traditional waveform technology approaches.
• DEC 15, 2022 – Nestlé invested over CHF 100 million by 2030 in low-carbon logistics for its three international water brands – S. Pellegrino, Acqua Panna and Perrier. This investment will focus on optimizing logistics routes and accelerating train transport, increasing the use of alternative fuels and transportation options and testing innovative alternative transportation options. By eliminating unnecessary journeys and shifting towards alternative modes of transport, Nestlé’s international water brands will be able to reduce their total greenhouse gas emissions and contribute to Nestlé’s 2050 net zero commitment.

Ace Matrix Analysis

The Ace Matrix provided in the report would help to understand how the major key players involved in this industry are performing as we provide a ranking for these companies based on various factors such as service features & innovations, scalability, innovation of services, industry coverage, industry reach, and growth roadmap. Based on these factors, we rank the companies into four categories as Active, Cutting Edge, Emerging, and Innovators.

Report Scope

Research Methodology of Verified Market Research:

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our Sales Team at Verified Market Research.

Reasons to Purchase this Report

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
• Provision of market value (USD Billion) data for each segment and sub-segment
• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions and acquisitions in the past five years of companies profiled
• Extensive company profiles comprising of company overview, company insights, product benchmarking and SWOT analysis for the major market players
• The current as well as the future market outlook of the industry with respect to recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
• Includes an in-depth analysis of the market of various perspectives through Porter’s five forces analysis
• Provides insight into the market through Value Chain
• Market dynamics scenario, along with growth opportunities of the market in the years to come
• 6-month post-sales analyst support

Customization of the Report

• In case of any Queries or Customization Requirements please connect with our sales team, who will ensure that your requirements are met.